Capricor Therapeutics, Inc. (CAPR) Covered Calls

You can sell covered calls on Capricor Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CAPR (prices last updated Thu 12:00 PM ET):

Capricor Therapeutics, Inc. (CAPR) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
18.79 +1.88 18.76 18.81 817K - 0.6
Covered Calls For Capricor Therapeutics, Inc. (CAPR)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Nov 15 20 0.15 18.66 0.8% 146%
Dec 20 20 2.40 16.41 14.6% 144%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates with Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.